Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGD009 (Orlotamab) in Advanced B7-H3-Expressing Neoplasms
NCT02628535Phase 1Terminated
- Sponsor
- MacroGenics
- Start
- Sep 2015
- Primary completion
- Nov 2019
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of obrindatamab in mesothelioma, bladder cancer, melanoma and 10 more, sponsored by MacroGenics. Primary endpoint: Number of participants with adverse events. Started Sep 2015; status: terminated.
02
Drugs
obrindatamab
03
Conditions
mesotheliomabladder cancermelanomahead and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02628535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02628535.